PharmacoDB: An integrative database for mining in vitro anticancer drug screening studies

Nucleic Acids Research

Volumn 46, Issue D1, 2018, Pages D994-D1002

  Smirnov, Petr ^a,b   Kofia, Victor ^a   Maru, Alexander ^a   Freeman, Mark ^a   Ho, Chantal ^a   El Hachem, Nehme ^a   Adam, George Alexandru ^a,c   Ba Alawi, Wail ^a,b   Safikhani, Zhaleh ^a,b   Haibe Kains, Benjamin ^a,b,c,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SELUMETINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; DATA MINING; DOSE RESPONSE; DRUG DATABASE; DRUG DETERMINATION; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFORMATION PROCESSING; PHARMACODB DATABASE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; COMPUTER INTERFACE; PHARMACOGENETIC TESTING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DATA MINING; DATABASES, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PHARMACOGENOMIC TESTING; USER-COMPUTER INTERFACE;

EID: 85040914313     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkx911     Document Type: Article

References (40)

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z.A., Brenner, H., Dicker, D.J., Chimed-Orchir, O., Dandona, R., et al. (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32cancer groups, 1990 to 2015: A systematic analysis for the globalburden of disease study. JAMA Oncol., 3, 524-548.
2. Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D.M., Niu, B., McLellan, M.D., Uzunangelov, V.et al. (2014) Multiplatform analysis of 12 cancer types revealsmolecular classification within and across tissues of origin. Cell, 158, 929-944.
3. Ludwig, J.A., Weinstein, J.N. (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer, 5, 845-856.
4. Garraway, L.A., Verweij, J., Ballman, K.V. (2013) Precisiononcology: An overview. J. Clin. Oncol., 31, 1803-1805.
5. Sharma, S.V., Haber, D.A., Settleman, J. (2010) Cell line-basedplatforms to evaluate the therapeutic efficacy of candidate anticanceragents. Nat. Rev. Cancer, 10, 241-253.
6. Macarron, R., Banks, M.N., Bojanic, D., Burns, D.J., Cirovic, D.A., Garyantes, T., Green, D.V.S., Hertzberg, R.P., Janzen, W.P., Paslay, J.W.et al. (2011) Impact of high-throughput screening in biomedicalresearch. Nat. Rev. Drug Discov., 10, 188-195.
7. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. (2012) Systematic identification of genomic markers ofdrug sensitivity in cancer cells. Nature, 483, 570-575.
8. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. (2012) The Cancer Cell Line Encyclopedia enablespredictive modelling of anticancer drug sensitivity. Nature, 483, 603-607.
9. Daemen, A., Griffith, O.L., Heiser, L.M., Wang, N.J., Enache, O.M., Sanborn, Z., Pepin, F., Durinck, S., Korkola, J.E., Griffith, M., et al.(2013) Modeling precision treatment of breast cancer. Genome Biol., 14, R110.
10. Klijn, C., Durinck, S., Stawiski, E.W., Haverty, P.M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. (2015) Acomprehensive transcriptional portrait of human cancer cell lines.Nat. Biotechnol., 33, 306-312.
11. Haverty, P.M., Lin, E., Tan, J., Yu, Y., Lam, B., Lianoglou, S., Neve, R.M., Martin, S., Settleman, J., Yauch, R.L., et al. (2016)Reproducible pharmacogenomic profiling of cancer cell line panels.Nature, 533, 333-337.
12. Mpindi, J.P., Yadav, B., Ö stling, P., Gautam, P., Malani, D., Murumägi, A., Hirasawa, A., Kangaspeska, S., Wennerberg, K., Kallioniemi, O., et al. (2016) Consistency in drug response profiling.Nature, 540, E5-E6.
13. Iorio, F., Knijnenburg, T.A., Vis, D.J., Bignell, G.R., Menden, M.P., Schubert, M., Aben, N., Goncąlves, E., Barthorpe, S., Lightfoot, H.et al. (2016) A landscape of pharmacogenomic interactions in cancer.Cell, doi:10.1016/j.cell.2016.06.017.
14. Hatzis, C., Bedard, P.L., Juul Birkbak, N., Beck, A.H., Aerts, H.J.W.L., Stern, D.F., Shi, L., Clarke, R., Quackenbush, J., Haibe-Kains, B.(2014) Enhancing reproducibility in cancer drug screening: How do wemove forward? Cancer Res., doi:10.1158/0008-5472.CAN-14-0725.
15. Haverty, P.M., Lin, E., Tan, J., Yu, Y., Lam, B., Lianoglou, S., Neve, R.M., Martin, S., Settleman, J., Yauch, R.L., et al. (2016)Reproducible pharmacogenomic profiling of cancer cell line panels.Nature, 533, 333-337.
16. Cancer Cell Line Encyclopedia Consortium and Genomics of DrugSensitivity in Cancer Consortium (2015) Pharmacogenomicagreement between two cancer cell line data sets. Nature, 528, 84-87.
17. Safikhani, Z., El-Hachem, N., Quevedo, R., Smirnov, P., Goldenberg, A., Juul Birkbak, N., Mason, C., Hatzis, C., Shi, L., Aerts, H.J., et al. (2016) Assessment of pharmacogenomic agreement.F1000Res., 5, 825.
18. Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Juul-Birkbak, N., Hatzis, C., Shi, L., et al.(2016) Revisiting inconsistency in large pharmacogenomic studies.F1000Res., 5, 2333.
19. Smirnov, P., Safikhani, Z., El-Hachem, N., Wang, D., She, A., Olsen, C., Freeman, M., Selby, H., Gendoo, D.M., Grossman, P., et al. (2016)PharmacoGx: An R package for analysis of large pharmacogenomicdatasets. Bioinformatics, doi:10.1093/bioinformatics/btv723.
20. Seashore-Ludlow, B., Rees, M.G., Cheah, J.H., Cokol, M., Price, E.V., Coletti, M.E., Jones, V., Bodycombe, N.E., Soule, C.K., Gould, J., et al.(2015) Harnessing connectivity in a large-scale small-moleculesensitivity dataset. Cancer Discov., doi:10.1158/2159-8290.CD-15-0235.
21. Basu, A., Bodycombe, N.E., Cheah, J.H., Price, E.V., Liu, K., Schaefer, G.I., Ebright, R.Y., Stewart, M.L., Ito, D., Wang, S., et al.(2013) An interactive resource to identify cancer genetic and lineagedependencies targeted by small molecules. Cell, 154, 1151-1161.
22. Heiser, L.M., Sadanandam, A., Kuo, W.-L., Benz, S.C., Goldstein, T.C., Ng, S., Gibb, W.J., Wang, N.J., Ziyad, S., Tong, F., et al. (2011) Subtypeand pathway specific responses to anticancer compounds in breastcancer. Proc. Natl. Acad. Sci. U.S.A., 109, 2724-2729.
23. Bairoch, A. (2015) ExPASy-Cellosaurus. Cellosaurus, http://web.expasy.org/cellosaurus/.
24. Corsello, S.M., Bittker, J.A., Liu, Z., Gould, J., McCarren, P., Hirschman, J.E., Johnston, S.E., Vrcic, A., Wong, B., Khan, M., et al.(2017) The drug repurposing hub: A next-generation drug library andinformation resource. Nat. Med., 23, 405-408.
25. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014)DrugBank 4.0: Shedding new light on drug metabolism. Nucleic AcidsRes., 42, D1091-D1097.
26. Bento, A.P., Gaulton, A., Hersey, A., Bellis, L.J., Chambers, J., Davies, M., Kr üger, F.A., Light, Y., Mak, L., McGlinchey, S., et al.(2014) The ChEMBL bioactivity database: An update. Nucleic AcidsRes., 42, D1083-D1090.
27. Safran, M., Chalifa-Caspi, V., Shmueli, O., Olender, T., Lapidot, M., Rosen, N., Shmoish, M., Peter, Y., Glusman, G., Feldmesser, E., et al.(2003) Human gene-centric databases at the Weizmann Institute ofScience: GeneCards, UDB, CroW 21 and HORDE. Nucleic AcidsRes., 31, 142-146.
28. Rebhan, M., Chalifa-Caspi, V., Prilusky, J., Lancet, D. (1998)GeneCards: A novel functional genomics compendium withautomated data mining and query reformulation support.Bioinformatics, 14, 656-664.
29. Whirl-Carrillo, M., McDonagh, E.M., Hebert, J.M., Gong, L., Sangkuhl, K., Thorn, C.F., Altman, R.B., Klein, T.E. (2012)Pharmacogenomics knowledge for personalized medicine. Clin.Pharmacol. Ther., 92, 414-417.
30. Kaplun, A., Hogan, J.D., Schacherer, F., Peter, A.P., Krishna, S., Braun, B.R., Nambudiry, R., Nitu, M.G., Mallelwar, R. andAlbayrak, A. (2016) PGMD: A comprehensive manually curatedpharmacogenomic database. Pharmacogenomics J., 16, 124-128.
31. Dalabira, E., Viennas, E., Daki, E., Komianou, A., Bartsakoulia, M., Poulas, K., Katsila, T., Tzimas, G., Patrinos, G.P. (2014) DruGeVar:an online resource triangulating drugs with genes and genomicbiomarkers for clinical pharmacogenomics. Public Health Genomics, 17, 265-271.
32. Yadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M.M., Malani, D., Murumägi, A., Knowles, J., et al. (2014) Quantitative scoring of differential drugsensitivity for individually optimized anticancer therapies. Sci. Rep., 4, 5193.
33. Fallahi-Sichani, M., Honarnejad, S., Heiser, L.M., Gray, J.W. andSorger, P.K. (2013) Metrics other than potency reveal systematicvariation in responses to cancer drugs. Nat. Chem. Biol., 9, 708-714.
34. El-Hachem, N., Gendoo, D.M.A., Ghoraie, L.S., Safikhani, Z., Smirnov, P., Chung, C., Deng, K., Fang, A., Birkwood, E., Ho, C., et al.(2017) Integrative Cancer Pharmacogenomics to Infer Large-ScaleDrug Taxonomy. Cancer Res., 77, 3057-3069.
35. Hafner, M., Niepel, M., Chung, M., Sorger, P.K. (2016) Growthrate inhibition metrics correct for confounders in measuringsensitivity to cancer drugs. Nat. Methods, 6, 521-527.
36. Hafner, M., Niepel, M., Sorger, P.K. (2017) Alternative drugsensitivity metrics improve preclinical cancer pharmacogenomics.Nat. Biotechnol., 35, 500-502.
37. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K.N.et al. (2006) The Connectivity Map: Using gene-expression signaturesto connect small molecules, genes, and disease. Science, 313, 1929-1935.
38. El-Hachem, N., Grossmann, P., Blanchet-Cohen, A., Bateman, A.R., Bouchard, N., Archambault, J., Aerts, H.J.W.L., Haibe-Kains, B.(2016) Characterization of Conserved Toxicogenomic Responses inChemically Exposed Hepatocytes across Species and Platforms.Environ. Health Perspect., 124, 313-320.
39. Igarashi, Y., Nakatsu, N., Yamashita, T., Ono, A., Ohno, Y., Urushidani, T., Yamada, H. (2015) Open TG-GATEs: A large-scaletoxicogenomics database. Nucleic Acids Res., 43, D921-D927.
40. Ganter, B., Snyder, R.D., Halbert, D.N., Lee, M.D. (2006)Toxicogenomics in drug discovery and development: Mechanisticanalysis of compound/class-dependent effects using the DrugMatrixdatabase. Pharmacogenomics, 7, 1025-1044.